Literature DB >> 25921248

Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy.

N Lachmann1,2, K Czarnecki1,2, S Brennig1,2, R Phaltane1,2, M Heise1,2, N Heinz2, H Kempf3, D Dilloo4, V Kaever5, A Schambach2,6, M Heuser7, T Moritz1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25921248     DOI： 10.1038/leu.2015.108

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  Marrow protection - transduction of hematopoietic cells with drug resistance genes.

Authors:  T Moritz; D A Williams
Journal:  Cytotherapy       Date:  2001       Impact factor: 5.414

Review 2.  Survival of the fittest: in vivo selection and stem cell gene therapy.

Authors:  Tobias Neff; Brian C Beard; Hans-Peter Kiem
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

3.  Extended survival of glioblastoma patients after chemoprotective HSC gene therapy.

Authors:  Jennifer E Adair; Brian C Beard; Grant D Trobridge; Tobias Neff; Jason K Rockhill; Daniel L Silbergeld; Maciej M Mrugala; Hans-Peter Kiem
Journal:  Sci Transl Med       Date:  2012-05-09       Impact factor: 17.956

4.  Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells.

Authors:  W Bardenheuer; K Lehmberg; I Rattmann; A Brueckner; A Schneider; U R Sorg; S Seeber; T Moritz; M Flasshove
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

5.  Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model.

Authors:  Ina Rattmann; Veronika Kleff; Ursula R Sorg; Walter Bardenheuer; Annette Brueckner; Ralf A Hilger; Bertram Opalka; Siegfried Seeber; Michael Flasshove; Thomas Moritz
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

6.  Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

Authors:  K R Rai; B L Peterson; F R Appelbaum; J Kolitz; L Elias; L Shepherd; J Hines; G A Threatte; R A Larson; B D Cheson; C A Schiffer
Journal:  N Engl J Med       Date:  2000-12-14       Impact factor: 91.245

7.  Requirement for deoxycytidine kinase in T and B lymphocyte development.

Authors:  Gerald Toy; Wayne R Austin; Hsiang-I Liao; Donghui Cheng; Arun Singh; Dean O Campbell; Tomo-o Ishikawa; Lynn W Lehmann; Nagichettiar Satyamurthy; Michael E Phelps; Harvey R Herschman; Johannes Czernin; Owen N Witte; Caius G Radu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-31       Impact factor: 11.205

8.  Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.

Authors:  Jennifer E Adair; Sandra K Johnston; Maciej M Mrugala; Brian C Beard; Laura A Guyman; Anne L Baldock; Carly A Bridge; Andrea Hawkins-Daarud; Jennifer L Gori; Donald E Born; Luis F Gonzalez-Cuyar; Daniel L Silbergeld; Russell C Rockne; Barry E Storer; Jason K Rockhill; Kristin R Swanson; Hans-Peter Kiem
Journal:  J Clin Invest       Date:  2014-08-08       Impact factor: 14.808

9.  Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery.

Authors:  R Zufferey; T Dull; R J Mandel; A Bukovsky; D Quiroz; L Naldini; D Trono
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

10.  Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.

Authors:  Magdalena Klanova; Lucie Lorkova; Ondrej Vit; Bokang Maswabi; Jan Molinsky; Jana Pospisilova; Petra Vockova; Cory Mavis; Lucie Lateckova; Vojtech Kulvait; Dana Vejmelkova; Radek Jaksa; Francisco Hernandez; Marek Trneny; Martin Vokurka; Jiri Petrak; Pavel Klener
Journal:  Mol Cancer       Date:  2014-06-27       Impact factor: 27.401
View more
  2 in total

1.  Function and Safety of Lentivirus-Mediated Gene Transfer for CSF2RA-Deficiency.

Authors:  Miriam Hetzel; Takuji Suzuki; Anna Rafiei Hashtchin; Paritha Arumugam; Brenna Carey; Marc Schwabbauer; Alexandra Kuhn; Johann Meyer; Axel Schambach; Johannes Van Der Loo; Thomas Moritz; Bruce C Trapnell; Nico Lachmann
Journal:  Hum Gene Ther Methods       Date:  2017-08-30       Impact factor: 2.396

2.  Murine iPSC-Derived Macrophages as a Tool for Disease Modeling of Hereditary Pulmonary Alveolar Proteinosis due to Csf2rb Deficiency.

Authors:  Adele Mucci; Jessica Kunkiel; Takuji Suzuki; Sebastian Brennig; Silke Glage; Mark P Kühnel; Mania Ackermann; Christine Happle; Alexandra Kuhn; Axel Schambach; Bruce C Trapnell; Gesine Hansen; Thomas Moritz; Nico Lachmann
Journal:  Stem Cell Reports       Date:  2016-07-21       Impact factor: 7.765
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.